Biosimilars
Experience to realize the potential
The biologics market is rife with opportunities for biopharma companies to deliver on the promise of lowering costs and increasing availability of this highly innovative class of drugs. But these opportunities are accompanied with risks: An evolving regulatory approval environment, scientific challenges and more stringent stakeholder demands for proof of value and safety.
Whether the end goal is gaining regulatory approval for a product that mimics the active pathway of an existing biologic (biosimilar), introducing a follow-on product with a superior clinical profile (biobetter), or minimizing competitive threats, the factors that determine the success of your program are the same:
- Optimizing clinical development strategy
- Navigating regulatory complexities
- Selecting high opportunity markets
- Minimizing the risk of exposure to competitive biosimilars
Backed by our extensive biologics experience, Quintiles offers an integrated biosimilar solution to overcome these challenges. Click the image below to learn how.
We have helped develop or commercialize nine of the 10 top best selling biologics of 2009. Quintiles can help maximize the value of your biosimilar investment - contact us to learn how.
